About Allergy and Immunology Division

Adult Allergy and Immunology Division, Hamad Medical Corporation, Doha, Qatar, established in 2010, serves adults with allergic and immunodeficiency diseases with the highest quality of care to patients with the utmost compassion through effective leadership, the promotion of excellence, and ongoing education and research.

The service currently includes the following:

Specialized Clinics: focuses on general allergy, severe asthma, urticaria/ angioedema, drug and food allergies, anaphylaxis, and immunodeficiency diseases. Also, we founded a clinical pharmacy (PCP) clinic to improve medication usage by patients, and allergy biologics review clinics.

Allergy Lab: operates various diagnostic and therapeutic procedures, including skin prick test, skin patch test, oral food challenge, drug challenge, and desensitization.

Infusion and Medication Administration Service: takes care of immunoglobulin administration (intravenous or subcutaneous) for patients with immunodeficiencies as a daycare service, with two monitored beds, subcutaneous and sublingual immunotherapy, and administration of different biologics.

Research Lab: actively involves clinical and translational research with multiple grants from the Medical Research Center (MRC)-HMC and Qatar National Research Foundation (QNRF). The ongoing research includes projects to identify pollen and fungal spore patterns and their impact on health and establishes the Qatar pollen calendar, and studies to identify various biomarkers in asthma, urticaria, primary immunodeficiency, and others.

The Allergy and Immunology Division runs a Combined (pediatric and adult) Allergy and Immunology Fellowship Program, which is a well-structured ACGME-I accredited. The program is for three years and offers 2 posts per year for fellows for training.

The service is actively involved in patient education and collaborates with various patients’ groups. Patient awareness is conducted through the HMC web portal and the wider media.

Multiple accreditations have been received, including World Allergy Organization (WAO) Centers of Excellence (WCOE) since 2020, Urticaria Center of Reference and Excellence (UCARE) since 2018, and Angioedema Center of Reference and Excellence (ACARE) since 2020 by the Global Allergy and Asthma European Network (GA²LEN).

Maryam Al-Nesf Al-Mansouri, MD, ABHS, MScR, FCCP, FACAAI
Head of Allergy and Immunology Division, HMC, Qatar